CR5926A - Combinaciones de estatina-eter carboxialquilico - Google Patents
Combinaciones de estatina-eter carboxialquilicoInfo
- Publication number
- CR5926A CR5926A CR5926A CR5926A CR5926A CR 5926 A CR5926 A CR 5926A CR 5926 A CR5926 A CR 5926A CR 5926 A CR5926 A CR 5926A CR 5926 A CR5926 A CR 5926A
- Authority
- CR
- Costa Rica
- Prior art keywords
- statin
- combinations
- carboxyalkyl ether
- pharmaceutically
- ether
- Prior art date
Links
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 title 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6937597P | 1997-12-12 | 1997-12-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR5926A true CR5926A (es) | 2000-03-06 |
Family
ID=22088573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR5926A CR5926A (es) | 1997-12-12 | 1998-12-10 | Combinaciones de estatina-eter carboxialquilico |
Country Status (30)
| Country | Link |
|---|---|
| EP (1) | EP1045691B1 (enExample) |
| JP (1) | JP2002508320A (enExample) |
| KR (1) | KR20010033003A (enExample) |
| AR (1) | AR017851A1 (enExample) |
| AT (1) | ATE285762T1 (enExample) |
| AU (1) | AU754089B2 (enExample) |
| BR (1) | BR9813542A (enExample) |
| CA (1) | CA2304612A1 (enExample) |
| CO (1) | CO4970816A1 (enExample) |
| CR (1) | CR5926A (enExample) |
| CU (1) | CU20000140A7 (enExample) |
| DE (1) | DE69828442T2 (enExample) |
| DK (1) | DK1045691T3 (enExample) |
| ES (1) | ES2230733T3 (enExample) |
| GT (1) | GT199800196A (enExample) |
| HN (1) | HN1998000185A (enExample) |
| HU (1) | HUP0004547A3 (enExample) |
| IL (1) | IL135349A0 (enExample) |
| IS (1) | IS2150B (enExample) |
| MY (1) | MY118381A (enExample) |
| NO (1) | NO20002966D0 (enExample) |
| NZ (1) | NZ503982A (enExample) |
| PA (1) | PA8464601A1 (enExample) |
| PE (1) | PE20000017A1 (enExample) |
| PL (1) | PL341066A1 (enExample) |
| PT (1) | PT1045691E (enExample) |
| SV (1) | SV1998000146A (enExample) |
| UY (1) | UY25299A1 (enExample) |
| WO (1) | WO1999030704A1 (enExample) |
| ZA (1) | ZA9811348B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030105154A1 (en) | 2001-10-24 | 2003-06-05 | Bisgaier Charles Larry | Statin-carboxyalkylether combinations |
| US6861555B2 (en) | 2000-01-25 | 2005-03-01 | Warner-Lambert Company | Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith |
| KR20010033017A (ko) * | 1997-12-12 | 2001-04-25 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 과지질혈증 치료제인 스타틴-ＬＰ(ａ) 억제제의 병용 제제 |
| SK4122001A3 (en) * | 1998-09-30 | 2002-06-04 | Warner Lambert Co | Method for preventing or delaying catheter-based revascularization |
| US6562864B1 (en) * | 1999-09-02 | 2003-05-13 | Drake Larson | Catechin multimers as therapeutic drug delivery agents |
| IN191580B (enExample) * | 1999-12-17 | 2003-12-06 | Ranbaxy Lab Ltd | |
| GEP20053428B (en) | 2000-01-25 | 2005-01-25 | Warner Lambert Co | Calcium Dicarboxylate Ethers, Methods of Making Same, and Treatment of Vascular Disease and Diabetes Therewith |
| AU2001256278A1 (en) * | 2000-04-18 | 2001-10-30 | Bayer Aktiengesellschaft | Use of cse inhibitors for treating heart failure |
| SK15132002A3 (sk) * | 2000-04-26 | 2003-08-05 | Warner-Lambert Company | Antihypertenzné činidlá a ich použitie |
| US6689807B1 (en) * | 2000-06-08 | 2004-02-10 | Caritas St. Elizabeth's Medical Center Of Boston, Inc. | HMG CoA reductase inhibitors for promoting angiogenesis |
| HUP0500616A3 (en) * | 2001-08-16 | 2011-07-28 | Teva Pharma | Processes for preparing calcium salt forms of statins |
| KR20040026705A (ko) | 2001-08-16 | 2004-03-31 | 테바 파마슈티컬 인더스트리즈 리미티드 | 스타틴의 칼슘 염 형태의 제조 방법 |
| US20050026979A1 (en) * | 2003-07-31 | 2005-02-03 | Maha Ghazzi | Methods for treating inflammation and inflammation-associated diseases with a statin and ether |
| WO2013103842A1 (en) * | 2012-01-06 | 2013-07-11 | Michigan Life Therapeutics, Llc | Methods of reducing risk of cardiovascular disease |
| JP2018536710A (ja) | 2015-11-06 | 2018-12-13 | ジェンファイア・セラピューティクス・インコーポレイテッドＧｅｍｐｈｉｒｅ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 混合型脂質異常症の治療 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5648387A (en) * | 1995-03-24 | 1997-07-15 | Warner-Lambert Company | Carboxyalkylethers, formulations, and treatment of vascular diseases |
-
1998
- 1998-11-12 NZ NZ503982A patent/NZ503982A/en unknown
- 1998-11-20 WO PCT/US1998/024679 patent/WO1999030704A1/en not_active Ceased
- 1998-11-20 AU AU15915/99A patent/AU754089B2/en not_active Ceased
- 1998-11-20 AT AT98960278T patent/ATE285762T1/de not_active IP Right Cessation
- 1998-11-20 EP EP98960278A patent/EP1045691B1/en not_active Expired - Lifetime
- 1998-11-20 PL PL98341066A patent/PL341066A1/xx unknown
- 1998-11-20 DE DE69828442T patent/DE69828442T2/de not_active Expired - Lifetime
- 1998-11-20 HU HU0004547A patent/HUP0004547A3/hu unknown
- 1998-11-20 IL IL13534998A patent/IL135349A0/xx unknown
- 1998-11-20 PT PT98960278T patent/PT1045691E/pt unknown
- 1998-11-20 KR KR1020007006355A patent/KR20010033003A/ko not_active Ceased
- 1998-11-20 DK DK98960278T patent/DK1045691T3/da active
- 1998-11-20 CA CA002304612A patent/CA2304612A1/en not_active Abandoned
- 1998-11-20 BR BR9813542-2A patent/BR9813542A/pt not_active Application Discontinuation
- 1998-11-20 JP JP2000538687A patent/JP2002508320A/ja active Pending
- 1998-11-20 ES ES98960278T patent/ES2230733T3/es not_active Expired - Lifetime
- 1998-12-09 HN HN1998000185A patent/HN1998000185A/es unknown
- 1998-12-10 ZA ZA9811348A patent/ZA9811348B/xx unknown
- 1998-12-10 CR CR5926A patent/CR5926A/es not_active Application Discontinuation
- 1998-12-10 MY MYPI98005579A patent/MY118381A/en unknown
- 1998-12-11 GT GT199800196A patent/GT199800196A/es unknown
- 1998-12-11 AR ARP980106321A patent/AR017851A1/es unknown
- 1998-12-11 PE PE1998001207A patent/PE20000017A1/es not_active Application Discontinuation
- 1998-12-11 PA PA19988464601A patent/PA8464601A1/es unknown
- 1998-12-11 CO CO98073828A patent/CO4970816A1/es unknown
- 1998-12-11 UY UY25299A patent/UY25299A1/es not_active Application Discontinuation
- 1998-12-11 SV SV1998000146A patent/SV1998000146A/es not_active Application Discontinuation
-
2000
- 2000-04-14 IS IS5445A patent/IS2150B/is unknown
- 2000-06-09 CU CU20000140A patent/CU20000140A7/es unknown
- 2000-06-09 NO NO20002966A patent/NO20002966D0/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR5926A (es) | Combinaciones de estatina-eter carboxialquilico | |
| ES2173978T3 (es) | Utilizacion de un alcohol graso insaturado. | |
| ES2157307T3 (es) | Composicion topica que contiene un antagonista de sustancia p. | |
| ES2192234T3 (es) | Composiciones farmaceuticas parenterales conteniendo sales de amonioalquilo de acidos 2-arilpropionicos. | |
| EA200300873A1 (ru) | Новая соль сукцинат o-десметилвенлафаксина | |
| AR033796A1 (es) | Composicion farmaceutica | |
| KR980000447A (ko) | 미르타자핀과 하나 이상의 선택적인 세로토닌 재이용 저해제로 이루어진 약학 조성물 | |
| BR9801989A (pt) | Pellets entéricos de fluoxetina. | |
| ES2176684T3 (es) | Nuevas asociaciones de principios activos que contienen clopidogrel y un antitrombotico. | |
| EA200300081A1 (ru) | Гидрогель-управляемая лекарственная форма | |
| GT199700009A (es) | Terapia combinada para la osteoporosis. | |
| PA8506101A1 (es) | Uso de un compuesto acat para fabricar una composicion farmaceutica | |
| AR012247A1 (es) | Composiciones farmaceuticas y su uso para la preparacion de medicamentos destinados a prevenir y tratar las enfermedades tromboembolicas arteriales | |
| BR9709062A (pt) | Composto, composição farmacêutica, e, uso de um composto. | |
| BR9909138A (pt) | Combinação para o tratamento de dependência de álcool e drogas contendo um antagonista de opióide e um modulador de complexo receptor de nmda | |
| AR012853A1 (es) | Formulacion inyectable transparente de compuesto anestesico | |
| ES2160680T3 (es) | Utilizacion de un antagonista de sustancia p en una composicion farmaceutica. | |
| TR200400228T4 (tr) | Psöryazinin tedavisinde kullanılacak maddeler | |
| ES2058646T3 (es) | Utilizacion de di-estiril-fenil-triglicoleter como inhibidor de la cristalizacion. | |
| AR000357A1 (es) | Utilización de un antagonista de sustancia p para la preparación de una composición farmacéutica de aplicación topica para tratar las manchas rojas cutaneas de origen neurogeno y especialmente la rosacea y el eritema pudico | |
| ES2156220T3 (es) | Preparacion transdermica que contiene un metabolito de loratidina con accion antihistaminica. | |
| CO4940448A1 (es) | Modificacion a cristal de una sustancia de medicamento | |
| AR011437A1 (es) | Composicion farmaceutica para el tratamiento de la migrana y el uso de la misma en la preparacion de un medicamento. | |
| AR035006A1 (es) | Derivado de naftiridin-dibenzo[a,d]ciclohepteno-10-acetico, composicion farmaceutica, y el uso de dicho derivado para la fabricacion de un medicamento. | |
| PA7801701A1 (es) | Compuestos ariltios |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal (granting procedure) |